Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity

NCT06679959 is registered in ClinicalTrials.gov with Ascletis Pharma (China) Co., Limited as lead sponsor.

NCT NCT06679959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity
Lead sponsor
Ascletis Pharma (China) Co., Limited
Phase
Phase 1/2
Overall status
Completed
Start date
September 16, 2024
Completion date
March 26, 2026
Enrollment
115 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic weight management